November 15, 2021 07:18 AM EST
R&D

Reel­ing from PD-1 slap­down, In­cyte stirs con­cerns with side ef­fects of oral PD-L1 — al­though drug is al­so 'clear­ly ac­tive'

Amber Tong

The re­jec­tion of its PD-1 in­hibitor, reti­fan­limab, was nev­er go­ing to be the end of In­cyte’s check­point sto­ry. Not on­ly was the biotech hold­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times